FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2397773641> ?p ?o ?g. }

• W2397773641 endingPage "71" @default.
• W2397773641 startingPage "65" @default.
• W2397773641 abstract "Objectives To evaluate equivalence in efficacy for rheumatoid arthritis (RA) and compare the safety of the biosimilar HD203 with innovator etanercept (ETN) plus methotrexate (MTX) (ClinicalTrials.gov NCT01270997 ). Methods Patients with active RA received 25 mg HD203 or ETN subcutaneously twice-weekly with MTX for 48 weeks in a phase III, multicentre, randomised, double-blind, parallel-group design. The primary end point was the proportion of patients achieving the American College of Rheumatology 20% response (ACR20) at week 24 for per-protocol study completer set (PPS). Secondary end points included ACR response criteria, ACRn, European League against Rheumatism (EULAR) response, change in Disease Activity Score 28 (DAS28), patient-reported outcomes, safety and immunogenicity. Results Of the 294 randomised patients (HD203, n=147; ETN, n=147), 233 comprised the 24-week PPS (n=115 and 118, respectively). ACR20 at week 24 was achieved by 83.48% and 81.36% of PPS patients, respectively, demonstrating equivalent efficacy within predefined margins of ±20% (treatment difference 2.12%, 95% CI −7.65% to 11.89%). Outcomes for secondary end points were consistent with the primary efficacy findings. Groups were comparable for overall incidences of treatment-emergent (all-causality) adverse events (AEs) (HD203 113 (76.9%) vs ETN 114 (78.1%) (p=0.804)), adverse drug reactions, serious AEs and discontinuations due to AEs. Few patients (HD203, n=8; ETN, n=3) tested positive for anti-drug antibodies. Conclusion The study met the primary objective of demonstrating equivalent efficacy of HD203 and ETN. HD203 was well tolerated, with safety comparable with ETN in this population of patients with RA. Trial registration number NCT01270997; Results." @default.
• W2397773641 created "2016-06-24" @default.
• W2397773641 creator A5004670805 @default.
• W2397773641 creator A5005854939 @default.
• W2397773641 creator A5009300665 @default.
• W2397773641 creator A5025401414 @default.
• W2397773641 creator A5026654916 @default.
• W2397773641 creator A5032199338 @default.
• W2397773641 creator A5035673535 @default.
• W2397773641 creator A5036999579 @default.
• W2397773641 creator A5054429863 @default.
• W2397773641 creator A5064707258 @default.
• W2397773641 creator A5070472813 @default.
• W2397773641 creator A5073586093 @default.
• W2397773641 creator A5077527676 @default.
• W2397773641 date "2016-02-23" @default.
• W2397773641 modified "2023-10-17" @default.
• W2397773641 title "A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study" @default.
• W2397773641 cites W1927365763 @default.
• W2397773641 cites W1995228104 @default.
• W2397773641 cites W2004057177 @default.
• W2397773641 cites W2013573826 @default.
• W2397773641 cites W2023048488 @default.
• W2397773641 cites W2023378412 @default.
• W2397773641 cites W2031785853 @default.
• W2397773641 cites W2038923378 @default.
• W2397773641 cites W2080875059 @default.
• W2397773641 cites W2081734937 @default.
• W2397773641 cites W2098767548 @default.
• W2397773641 cites W2100431243 @default.
• W2397773641 cites W2102907120 @default.
• W2397773641 cites W2108079348 @default.
• W2397773641 cites W2113182448 @default.
• W2397773641 cites W2115498627 @default.
• W2397773641 cites W2116843833 @default.
• W2397773641 cites W2121050884 @default.
• W2397773641 cites W2128918690 @default.
• W2397773641 cites W2136731562 @default.
• W2397773641 cites W2141395406 @default.
• W2397773641 cites W2148853005 @default.
• W2397773641 cites W2148988489 @default.
• W2397773641 cites W2151444904 @default.
• W2397773641 cites W2152348310 @default.
• W2397773641 cites W2314052274 @default.
• W2397773641 cites W2328587823 @default.
• W2397773641 cites W2340084730 @default.
• W2397773641 cites W4249671262 @default.
• W2397773641 cites W4295125684 @default.
• W2397773641 doi "https://doi.org/10.1136/annrheumdis-2015-207613" @default.
• W2397773641 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26905864" @default.
• W2397773641 hasPublicationYear "2016" @default.
• W2397773641 type Work @default.
• W2397773641 sameAs 2397773641 @default.
• W2397773641 citedByCount "34" @default.
• W2397773641 countsByYear W23977736412016 @default.
• W2397773641 countsByYear W23977736412017 @default.
• W2397773641 countsByYear W23977736412018 @default.
• W2397773641 countsByYear W23977736412019 @default.
• W2397773641 countsByYear W23977736412020 @default.
• W2397773641 countsByYear W23977736412021 @default.
• W2397773641 countsByYear W23977736412022 @default.
• W2397773641 countsByYear W23977736412023 @default.
• W2397773641 crossrefType "journal-article" @default.
• W2397773641 hasAuthorship W2397773641A5004670805 @default.
• W2397773641 hasAuthorship W2397773641A5005854939 @default.
• W2397773641 hasAuthorship W2397773641A5009300665 @default.
• W2397773641 hasAuthorship W2397773641A5025401414 @default.
• W2397773641 hasAuthorship W2397773641A5026654916 @default.
• W2397773641 hasAuthorship W2397773641A5032199338 @default.
• W2397773641 hasAuthorship W2397773641A5035673535 @default.
• W2397773641 hasAuthorship W2397773641A5036999579 @default.
• W2397773641 hasAuthorship W2397773641A5054429863 @default.
• W2397773641 hasAuthorship W2397773641A5064707258 @default.
• W2397773641 hasAuthorship W2397773641A5070472813 @default.
• W2397773641 hasAuthorship W2397773641A5073586093 @default.
• W2397773641 hasAuthorship W2397773641A5077527676 @default.
• W2397773641 hasConcept C126322002 @default.
• W2397773641 hasConcept C168563851 @default.
• W2397773641 hasConcept C197934379 @default.
• W2397773641 hasConcept C198451711 @default.
• W2397773641 hasConcept C203092338 @default.
• W2397773641 hasConcept C2777226972 @default.
• W2397773641 hasConcept C2777489490 @default.
• W2397773641 hasConcept C2777575956 @default.
• W2397773641 hasConcept C2781059491 @default.
• W2397773641 hasConcept C71924100 @default.
• W2397773641 hasConceptScore W2397773641C126322002 @default.
• W2397773641 hasConceptScore W2397773641C168563851 @default.
• W2397773641 hasConceptScore W2397773641C197934379 @default.
• W2397773641 hasConceptScore W2397773641C198451711 @default.
• W2397773641 hasConceptScore W2397773641C203092338 @default.
• W2397773641 hasConceptScore W2397773641C2777226972 @default.
• W2397773641 hasConceptScore W2397773641C2777489490 @default.
• W2397773641 hasConceptScore W2397773641C2777575956 @default.
• W2397773641 hasConceptScore W2397773641C2781059491 @default.
• W2397773641 hasConceptScore W2397773641C71924100 @default.
• W2397773641 hasIssue "1" @default.
• W2397773641 hasLocation W23977736411 @default.

• next